search
Back to results

Orange Juice And Sugar Intervention Study (OASIS)

Primary Purpose

Cardiovascular Risk Factor, Type2 Diabetes Mellitus, Insulin Sensitivity

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Naturally-sweetened orange juice
Sugar-sweetened beverage
Sponsored by
University of California, Davis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Cardiovascular Risk Factor focused on measuring orange juice, sugar-sweetened beverage, triglyceride, low density lipoprotein cholesterol, apolipoprotein B, uric acid, de novo lipogenesis, hepatic triglyceride, hepatic glucose production, whole body insulin sensitivity

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: men and pre-menopausal women Body mass index: 20-35 kg/m2 Body weight > than 50 kg Self-reported stable body weight during the prior six months

Exclusion Criteria:

Fasting glucose >125 mg/dl Evidence of liver disorder (AST or ALT >200% upper limit of normal range) Evidence of kidney disorder (>2.0 mg/dl creatinine) Evidence of thyroid disorder (out of normal range) Systolic blood pressure consistently over 140 mmHg or diastolic blood pressure over 90 mmHg Triglycerides > 400 mg/dl LDL-C > 160 mg/dl in combination with Chol:HDL > 4 Hemoglobin < 10 g/dL Pregnant or lactating women Current, prior (within 12 months), or anticipated use of any hypolipidemic or anti-diabetic agents.

Use of thyroid, anti-hypertensive, anti-depressant, weight loss medications or any other medication which, in the opinion of the investigator, may confound study results Use of tobacco Strenuous exerciser (>3.5 hours/week at a level more vigorous than walking) Surgery for weight loss Diet exclusions: Food allergies, special dietary restrictions, routine consumption of less than 3 meals/day, routine ingestion of more than 2 sugar-sweetened beverages or 1 alcoholic beverage/day, unwillingness to consume any food on study menu Veins that are assessed by the R.N.s as being unsuitable for long-term infusions and multiple blood draws from a catheter.

Pre-existing claustrophobia or metal implants that preclude magnetic resonance imaging Any other condition that, in the opinion of the investigators, would put the subject at risk

-

Sites / Locations

  • University of California, Davis

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Naturally-sweetened orange juice

Sugar-sweetened beverage

Arm Description

Naturally-sweetened orange juice Form: Beverage Daily dosage: 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 4 weeks

Sugar-sweetened beverage Form: Beverage Daily dosage: 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 4 weeks

Outcomes

Primary Outcome Measures

Low density lipoprotein cholesterol (LDL-C)
Plasma LDL-C concentration
Apolipoprotein B (apoB)
Plasma apoB concentration
Uric acid
Plasma uric acid concentration
de novo lipogenesis (DNL)
%Fractional rate DNL
Hepatic triglyceride
%hepatic triglyceride
Endogenous glucose production
Endogenous glucose production during hyperinsulinemic clamp

Secondary Outcome Measures

Postprandial triglyceride
Plasma postprandial triglyceride concentration
3-(3'-hydroxy-4'-methoxyphenyl)hydracrylic
Urine concentration of 3-(3'-hydroxy-4'-methoxyphenyl)hydracrylic
hesperetin-3'-O-glucuronide
Urine concentration hesperetin-3'-O-glucuronide
hesperetin-3'-sulfate
Urine concentration hesperetin-3'-sulfate
Apolipoprotein CIII (apoCIII)
Fasting and postprandial plasma apoCIII concentration
non-high density lipoprotein cholesterol (non-HDL-C)
Plasma non-HDL-C concentration

Full Information

First Posted
April 10, 2018
Last Updated
June 13, 2023
Sponsor
University of California, Davis
Collaborators
Touro University, California
search

1. Study Identification

Unique Protocol Identification Number
NCT03527277
Brief Title
Orange Juice And Sugar Intervention Study
Acronym
OASIS
Official Title
The Effects of Orange Juice Compared With Sugar-sweetened Beverage on Risk Factors and Metabolic Processes Associated With the Development of Cardiovascular Disease and Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
June 1, 2018 (Actual)
Primary Completion Date
May 28, 2023 (Actual)
Study Completion Date
May 28, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, Davis
Collaborators
Touro University, California

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objectives of this proposal are to address the gaps in knowledge regarding the metabolic effects of consuming orange juice, the most frequently consumed fruit juice in this country, compared to sugar-sweetened beverage.
Detailed Description
Specific Aims: There is considerable epidemiological evidence that demonstrates associations between added sugar/sugar-sweetened beverage consumption and increased risk for or prevalence of chronic diseases such as cardiovascular disease (CVD), type 2 diabetes (T2D), metabolic syndrome, and gout. Especially concerning is recent evidence from National Health and Nutrition Examination Survey III that demonstrates that there is increased risk of CVD mortality with increased intake of added sugar across quintiles (Yang, 2014). Even the US mean added sugar intake, 15% of daily calories, was associated with an 18% increase in risk of CVD mortality over 15 years. The results from the investigator's recently completed study (1R01 HL09133) corroborate these findings (Stanhope, 2015). They demonstrate that supplementing the ad libitum diets of young adults with beverages containing 0, 10, 17.5 or 25% of daily energy requirement (Ereq) as high fructose corn syrup (HFCS) affects lipid/lipoprotein risk factors for CVD in a dose response manner. Specifically, levels of nonHDL-cholesterol(C), LDL-C, apolipoprotein B (apoB), and postprandial triglycerides (TG) increased linearly over a 2-week period with increasing doses of HFCS. Furthermore, even the participants consuming the 10% Ereq dose exhibited increased levels of these risk factors compared to baseline. These and similar results have helped to lead to reductions in soda consumption in this country, and new dietary guidelines and FDA food labeling requirements to promote reductions in added sugar consumption. However, there are gaps in knowledge about other sugar-containing foods that lead to public confusion concerning healthier options for soda, and impede further progress in implementing public health policies that will promote further reductions in soda consumption. One such food is naturally-sweetened fruit juice. The amount of sugar in fruit juice is comparable to the amount in soda. Because of this, a consumer seeking answers on the internet will find many articles in which experts state or suggest that the effects of consuming fruit juice are as detrimental as or even worse than those of soda. However, in contrast to soda, fruit juice contains micronutrients and bioactives that may promote health. Therefore the consumer can also find numerous articles on the internet where the health benefits of fruit juice and these bioactives are extolled. There are a limited number of clinical dietary intervention studies that have directly compared the metabolic effects of consuming fruit juice and sugar-sweetened beverage, and their results are not conclusive. Thus we will pursue the following Specific Aims: Specific Aim 1: To compare the weight-independent effects of consuming 25%Ereq as orange juice or sugar-sweetened beverages for 4 weeks on risk factors for CVD and other chronic disease in normal weight and overweight men and women. Specific Aim 2: To mechanistically compare the weight-independent effects of consuming 25%Ereq as orange juice or sugar-sweetened beverages on metabolic processes associated with the development of CVD and T2D in normal weight and overweight men and women. Specific Aim 3: To relate the changes assessed under Specific Aims 1 and 2 to the changes in the urinary levels of metabolites and catabolites of the main flavanones in orange juice, hesperetin and naringenin.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiovascular Risk Factor, Type2 Diabetes Mellitus, Insulin Sensitivity, Metabolic Syndrome
Keywords
orange juice, sugar-sweetened beverage, triglyceride, low density lipoprotein cholesterol, apolipoprotein B, uric acid, de novo lipogenesis, hepatic triglyceride, hepatic glucose production, whole body insulin sensitivity

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized controlled trial
Masking
Outcomes Assessor
Masking Description
All outcomes will be analyzed/assessed by subject identity number, which are assigned prior to randomization to experimental arm.
Allocation
Randomized
Enrollment
56 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Naturally-sweetened orange juice
Arm Type
Experimental
Arm Description
Naturally-sweetened orange juice Form: Beverage Daily dosage: 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 4 weeks
Arm Title
Sugar-sweetened beverage
Arm Type
Active Comparator
Arm Description
Sugar-sweetened beverage Form: Beverage Daily dosage: 25% of daily energy requirement Frequency: Divided into 3 servings/day Duration: 4 weeks
Intervention Type
Other
Intervention Name(s)
Naturally-sweetened orange juice
Intervention Description
Commercially-available ready-to-serve refrigerated orange juice
Intervention Type
Other
Intervention Name(s)
Sugar-sweetened beverage
Intervention Description
Sugar-sweetened water flavored with Kool-Aid (TM)
Primary Outcome Measure Information:
Title
Low density lipoprotein cholesterol (LDL-C)
Description
Plasma LDL-C concentration
Time Frame
4 weeks
Title
Apolipoprotein B (apoB)
Description
Plasma apoB concentration
Time Frame
4 weeks
Title
Uric acid
Description
Plasma uric acid concentration
Time Frame
4 weeks
Title
de novo lipogenesis (DNL)
Description
%Fractional rate DNL
Time Frame
4 weeks
Title
Hepatic triglyceride
Description
%hepatic triglyceride
Time Frame
4 weeks
Title
Endogenous glucose production
Description
Endogenous glucose production during hyperinsulinemic clamp
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Postprandial triglyceride
Description
Plasma postprandial triglyceride concentration
Time Frame
4 weeks
Title
3-(3'-hydroxy-4'-methoxyphenyl)hydracrylic
Description
Urine concentration of 3-(3'-hydroxy-4'-methoxyphenyl)hydracrylic
Time Frame
4 weeks
Title
hesperetin-3'-O-glucuronide
Description
Urine concentration hesperetin-3'-O-glucuronide
Time Frame
4 weeks
Title
hesperetin-3'-sulfate
Description
Urine concentration hesperetin-3'-sulfate
Time Frame
4 weeks
Title
Apolipoprotein CIII (apoCIII)
Description
Fasting and postprandial plasma apoCIII concentration
Time Frame
4 weeks
Title
non-high density lipoprotein cholesterol (non-HDL-C)
Description
Plasma non-HDL-C concentration
Time Frame
4 weeks
Other Pre-specified Outcome Measures:
Title
Gluconeogenesis
Description
Determined from glucose isotopomer distribution
Time Frame
4 weeks
Title
Glycogenolysis
Description
Endogenous glucose production minus gluconeogenesis
Time Frame
4 weeks
Title
Lipolysis
Description
Determined from glycerol isotopomer distribution
Time Frame
4 weeks
Title
Triglyceride production
Description
Determined from glycerol isotopomer distribution
Time Frame
4 weeks
Title
Energy expenditure
Description
Postprandial energy expenditure
Time Frame
4 weeks
Title
Fat oxidation
Description
Postprandial fat oxidation
Time Frame
4 weeks
Title
Hesperetin-7-O-glucuronide
Description
Urine concentration hesperetin-7-O-glucuronide
Time Frame
4 weeks
Title
Naringenin-4'-O-glucuronide
Description
Urine concentration naringenin-4'-O-glucuronide
Time Frame
4 weeks
Title
Naringen-7-O-glucuronide
Description
Urine concentration naringen-7-O-glucuronide
Time Frame
4 weeks
Title
Fecal microbiota
Description
Fecal relative bacterial abundance
Time Frame
4 weeks
Title
Insulin
Description
fasting and postprandial plasma insulin concentration
Time Frame
4 week
Title
glucose
Description
fasting and postprandial plasma glucose concentration
Time Frame
glucose
Title
Apolipoprotein E (apoE)
Description
plasma apoE concentration
Time Frame
4 weeks
Title
high sensitivity C reactive protein (CRP)
Description
plasma CRP concentration
Time Frame
4 weeks
Title
aspartate aminotransferase (AST)
Description
plasma AST concentration
Time Frame
4 weeks
Title
alanine aminotransferase (ALT)
Description
plasma ALT concentration
Time Frame
4 weeks
Title
gamma-glutamyl transferase (GGT)
Description
plasma GGT concentration
Time Frame
4 weeks
Title
oxidized LDL (oxLDL)
Description
plasma oxLDL concentration
Time Frame
4 weeks
Title
malondialdehyde
Description
fasting and postprandial plasma malondialdehyde concentration
Time Frame
4 weeks
Title
total antioxidant status
Description
fasting and postprandial plasma total antioxidant status
Time Frame
4 weeks
Title
soluble vascular cellular adhesion molecule (sVCAM-1)
Description
plasma sVCAM-1 concentration
Time Frame
4 weeks
Title
monocyte chemotactic protein-1 (MCP-1)
Description
plasma MCP-1 concentration
Time Frame
4 weeks
Title
nitric oxide metabolite (NOx)
Description
plasma NOx concentration
Time Frame
4 weeks
Title
Diastolic and systolic blood pressure
Description
fasting and postprandial blood pressure
Time Frame
4 weeks
Title
Body fat
Description
%body fat
Time Frame
4 weeks
Title
Visceral fat
Description
Abdominal visceral fat volume
Time Frame
4 weeks
Title
Subcutaneous fat
Description
Abdominal subcutaneous fat volume
Time Frame
4 weeks
Title
Physical activity
Description
Assessed by accelerometer
Time Frame
4 weeks
Title
Eating motivation
Description
Assessed by 19 questions that are scored on a 5-point scale with 5 describing eating behavior driven by reasons other than hunger (i.e. emotions, social pressure)
Time Frame
4 weeks

10. Eligibility

Sex
All
Gender Based
Yes
Gender Eligibility Description
self-representation
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: men and pre-menopausal women Body mass index: 20-35 kg/m2 Body weight > than 50 kg Self-reported stable body weight during the prior six months Exclusion Criteria: Fasting glucose >125 mg/dl Evidence of liver disorder (AST or ALT >200% upper limit of normal range) Evidence of kidney disorder (>2.0 mg/dl creatinine) Evidence of thyroid disorder (out of normal range) Systolic blood pressure consistently over 140 mmHg or diastolic blood pressure over 90 mmHg Triglycerides > 400 mg/dl LDL-C > 160 mg/dl in combination with Chol:HDL > 4 Hemoglobin < 10 g/dL Pregnant or lactating women Current, prior (within 12 months), or anticipated use of any hypolipidemic or anti-diabetic agents. Use of thyroid, anti-hypertensive, anti-depressant, weight loss medications or any other medication which, in the opinion of the investigator, may confound study results Use of tobacco Strenuous exerciser (>3.5 hours/week at a level more vigorous than walking) Surgery for weight loss Diet exclusions: Food allergies, special dietary restrictions, routine consumption of less than 3 meals/day, routine ingestion of more than 2 sugar-sweetened beverages or 1 alcoholic beverage/day, unwillingness to consume any food on study menu Veins that are assessed by the R.N.s as being unsuitable for long-term infusions and multiple blood draws from a catheter. Pre-existing claustrophobia or metal implants that preclude magnetic resonance imaging Any other condition that, in the opinion of the investigators, would put the subject at risk -
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kimber L Stanhope, Ph.D.
Organizational Affiliation
University of California, Davis
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California, Davis
City
Davis
State/Province
California
ZIP/Postal Code
95616
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Final dataset will include data collected specifically for the study and data provided during screening in the medical history form. This includes some demographic information and data regarding family history of disease. We will make data and demographic information available to other investigators upon request. The dataset will be stripped of all unique identifiers and subject characteristics and prepared in accordance with all HIPAA regulations prior to release for sharing. Study outcome results will be submitted to ClinicalTrials.gov no later than one year after the trial's primary completion date.
IPD Sharing Time Frame
One year after the end of study--January 31, 2025
IPD Sharing Access Criteria
We will make data and demographic information available to investigators who submit an outline with: Hypotheses/aims Assurance that the data will be stored on secured computer Assurance that access will be limited to those named in the proposal Commitment to destroy/return the data after analyses are completed Guarantee that the grant and the primary investigators will be acknowledged in any publications arising from these data.
Citations:
PubMed Identifier
24493081
Citation
Yang Q, Zhang Z, Gregg EW, Flanders WD, Merritt R, Hu FB. Added sugar intake and cardiovascular diseases mortality among US adults. JAMA Intern Med. 2014 Apr;174(4):516-24. doi: 10.1001/jamainternmed.2013.13563.
Results Reference
result
PubMed Identifier
25904601
Citation
Stanhope KL, Medici V, Bremer AA, Lee V, Lam HD, Nunez MV, Chen GX, Keim NL, Havel PJ. A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. Am J Clin Nutr. 2015 Jun;101(6):1144-54. doi: 10.3945/ajcn.114.100461. Epub 2015 Apr 22.
Results Reference
result
Links:
URL
https://studypages.com/s/a-study-of-the-effect-of-orange-juice-or-sugar-sweetened-beverages-on-risk-factors-for-type-2-diabetes-and-cardiovascular-disease-564592/
Description
Learn more or sign up for the study here!

Learn more about this trial

Orange Juice And Sugar Intervention Study

We'll reach out to this number within 24 hrs